These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2106410)

  • 1. Intravegetation antimicrobial distribution in aortic endocarditis analyzed by computer-generated model. Implications for treatment.
    Bayer AS; Crowell D; Nast CC; Norman DC; Borrelli RL
    Chest; 1990 Mar; 97(3):611-7. PubMed ID: 2106410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
    Xiong YQ; Caillon J; Kergueris MF; Drugeon H; Baron D; Potel G; Bayer AS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):823-6. PubMed ID: 9087497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis.
    Bayer AS; Crowell DJ; Yih J; Bradley DW; Norman DC
    J Infect Dis; 1988 Aug; 158(2):355-9. PubMed ID: 3042875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computation of drug concentrations in endocardial vegetations in patients during antibiotic therapy.
    Maire P; Barbaut X; Vergnaud JM; el Brouzi M; Confesson MA; Pivot C; Chuzeville M; Ivanoff N; Brazier JL; Jelliffe RW
    Int J Biomed Comput; 1994 Jun; 36(1-2):77-85. PubMed ID: 7927862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aminoglycoside determinations calculated in endocarditis vegetations. Relations with clinical practices during infectious endocarditis treatment with amikacin].
    Confesson MA; Barbaut X; Maire P; Vergnaud JM; el Brouzi A; Jelliffe RW
    Therapie; 1994; 49(1):27-34. PubMed ID: 8091362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.
    Bugnon D; Potel G; Xiong YQ; Caillon J; Kergueris MF; Le Conte P; Baron D; Drugeon H
    Antimicrob Agents Chemother; 1996 May; 40(5):1164-9. PubMed ID: 8723459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa.
    Bayer AS; Park S; Ramos MC; Nast CC; Eftekhar F; Schiller NL
    Infect Immun; 1992 Oct; 60(10):3979-85. PubMed ID: 1398909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
    Bayer AS; Lam K; Norman D; Kim KS; Morrison JO
    Chemotherapy; 1985; 31(5):351-61. PubMed ID: 3931992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
    Bayer AS; Norman D; Kim KS
    Antimicrob Agents Chemother; 1985 Dec; 28(6):781-5. PubMed ID: 3909954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
    Halacová M; Průsa R; Kotaska K; Vávrová V
    Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both.
    Xiong YQ; Caillon J; Zhou XY; Potel G; Bugnon D; Le Conte P; Le Gallou F; Le Floch R; Baron D; Drugeon H
    J Antimicrob Chemother; 1995 May; 35(5):697-706. PubMed ID: 7592185
    [No Abstract]   [Full Text] [Related]  

  • 13. Oxygen-dependent differences in exopolysaccharide production and aminoglycoside inhibitory-bactericidal interactions with Pseudomonas aeruginosa--implications for endocarditis.
    Bayer AS; O'Brien T; Norman DC; Nast CC
    J Antimicrob Chemother; 1989 Jan; 23(1):21-35. PubMed ID: 2501267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic effects of monocytopenia, granulocytopenia and dexamethasone on the course of experimental Pseudomonas aeruginosa endocarditis in rabbits.
    Bayer AS; Yih J; Chiu CY; Nast CC
    Chemotherapy; 1989; 35(4):278-88. PubMed ID: 2504546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa.
    Bayer AS; Kim KS
    Chemotherapy; 1986; 32(4):364-73. PubMed ID: 2942342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of experimental Pseudomonas endocarditis with high-dose amikacin and ticarcillin.
    Choi C; Bayer AS; Fujita NK; Lam K; Guze LB; Yoshikawa TT
    Chemotherapy; 1983; 29(4):303-12. PubMed ID: 6872621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of impermeability variants of Pseudomonas aeruginosa isolated during unsuccessful therapy of experimental endocarditis.
    Bayer AS; Norman DC; Kim KS
    Antimicrob Agents Chemother; 1987 Jan; 31(1):70-5. PubMed ID: 3105442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental Escherichia coli endocarditis.
    Joly V; Pangon B; Vallois JM; Abel L; Brion N; Bure A; Chau NP; Contrepois A; Carbon C
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1632-9. PubMed ID: 3324957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis.
    Gengo FM; Mannion TW; Nightingale CH; Schentag JJ
    J Antimicrob Chemother; 1984 Dec; 14(6):619-31. PubMed ID: 6520062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.